Retatrutide da Kiba
Rage kiba ne ya jawo hankalin mutane game da retatrutide, wani maganin shiga uku da Eli Lilly ke ba da shi kowane mako. Sai dai wani sabon binciken bayan‑bayan na gwaje‑gwajen mataki na biyu, da aka wallafa a mujallar Diabetes, Obesity & Metabolism ta Ruotolo da abokan aiki, ya duba tasirin sa a jini. Sakamakon da ya fi jan hankali shi ne raguwar har zuwa 84.4 % a manyan kwayoyin lipoprotein masu ɗauke da triglyceride a masu cutar sukari na nau’i 2 (T2D), da kuma raguwar 76.6 % a waɗanda ba su da cutar.
Kafin kowa ya yi murna, akwai muhimman abubuwa uku da ya kamata a sani: wannan bincike ne na bayan‑bayan; retatrutide ba a amince da shi ba a matsayin magani; kuma shi magani ne da ke buƙatar takardar izini, ba kari ba. Don haka dole ne mu duba bayanan da hankali.
Hanyoyin Binciken Da Masana Suka Yi
Masana sun tattara bayanan alamomi daga gwaje‑gwajen biyu masu tsari iri‑iri, inda an yi amfani da placebo a mataki na biyu (ClinicalTrials.gov NCT04881760 da NCT04867785):
- Bincike 1 – Mutanen da ke da kiba kuma masu cutar sukari na nau’i 2 (T2D) sun samu retatrutide a kowane mako (0.5, 4, 8 ko 12 mg), ko dulaglutide 1.5 mg, ko placebo na tsawon makonni 36. Matsakaicin BMI ya kasance 35.4 kg/m².
- Bincike 2 – Mutanen da ke da kiba amma ba su da cutar sukari sun samu retatrutide a kowane mako (1, 4, 8 ko 12 mg) ko placebo na tsawon makonni 48. Matsakaicin BMI ya kai 37.4 kg/m².
An ɗauki samfurin jini ba tare da cin abinci ba a farkon gwaji da a lokacin magani. An auna lipids, apolipoproteins, nau’o’in lipoprotein da alamomin kumburi. Masu rubutun sun yi amfani da hanyoyin ƙididdiga (mixed models) don tantance bambancin da placebo ya haifar tun daga tushe. An ɗauki ƙimar p da aka daidaita da false discovery rate (FDR) ƙasa da 0.05 a matsayin mai ma’ana.
Sakamakon Lipids: ApoB, Kwayoyin LDL da Triglyceride‑Rich Lipoproteins
A cikin duka gwaje‑gwajen, retatrutide ya nuna raguwa mai ma’ana a alamomin da ke haifar da atherosclerosis. Takardar ta ba da manyan canje‑canjen da aka daidaita da placebo a matsayin “har zuwa” (Bincike 1 / Bincike 2):
| Alama | Bincike 1 (T2D) | Bincike 2 (ba T2D) |
|---|---|---|
| Cholesterol na Non‑HDL | har zuwa −21.0 % | har zuwa −26.9 % |
| Apolipoprotein B | −21.4 % | −24.2 % |
| Jimillar kwayoyin triglyceride‑rich lipoprotein (TRL) | −22.5 % | −33.7 % |
| Manyan kwayoyin TRL | −84.4 % | −76.6 % |
| TRL cholesterol | −29.4 % | −38.6 % |
| Jimillar kwayoyin LDL | −19.7 % | −23.5 % |
| Kananan kwayoyin LDL | −32.6 % | −32.3 % |
ApoB na da muhimmanci domin kowanne kwayar atherogenic – ko LDL, VLDL ko sauran remnant – yana dauke da kusan ƙwayar ApoB guda. Raguwa a ApoB na nuni da ƙananan yawan kwayoyin da ke shiga jijiyoyin jini, ba wai ƙarancin cholesterol a kowanne kwaya ba. Ragin kananan kwayoyin LDL da manyan TRL na nuna canjin gaba ɗaya a tsarin lipoprotein, ba wai kawai raguwar LDL‑C ba.
Alamar Kumburi: hsCRP da IL‑6
A cikin Bincike 2, wadda ba ta da cutar sukari, retatrutide ya haifar da raguwar 54.8 % a high‑sensitivity C‑reactive protein (hsCRP) da raguwar 29.6 % a interleukin‑6 (IL‑6). Waɗannan canje‑canjen ba su da ma’ana a Bincike 1.
Takardar ba ta bayyana dalilin wannan bambanci ba. Gwaje‑gwajen sun bambanta a cikin al’umma, tsawon lokaci (makonni 36 vs 48) da kuma iyakokin dose, don haka yana da haɗari a fassara sakamakon ba tare da nazarin cikakken rubutu ba.
Me Ya Faru Da Lp(a) Da Rarraba Dose‑by‑Dose?
Idan kana neman ƙididdigar Lp(a), takardar ba ta ba da kowanne ba, don haka ba za a iya yin wani ƙarar game da tasirin retatrutide a kan Lp(a) ba. Haka kuma, takardar ta ba da kawai manyan canje‑canjen “har zuwa”. Ba a haɗa kowanne adadi da takamaiman dose ba, don haka ikirarin alaƙar dose‑response zai wuce abin da ke cikin takardar. Don ganin ƙididdiga bisa ga dose, ciki har da sakamakon lipoprotein(a), masu karatu su karanta cikakken rubutun (DOI: 10.1111/dom.71200).
Me Ya Sa Wannan Yake Da Muhimmanci
Kiba da T2D na ƙara haɗarin cutar zuciya da jijiyoyi ta hanyar atherogenic dyslipidemia: ƙarin triglyceride‑rich remnants, ƙarin kananan kwayoyin LDL, da ƙarin kumburi. Masu rubutu sun ƙare da cewa retatrutide ya nuna raguwar lipoprotein atherogenic da kuma alamomin kumburi da ke da alaƙa da haɗarin cutar zuciya. Wannan alama ce mai kyau, amma alamomin ba su zama hujja ta ƙarshe ba. Wannan gwaje‑gwajen ba a tsara su don tantance rage haɗarin bugun zuciya ko zubewar jini ba, kuma binciken ba zai iya tabbatar da ko waɗannan canje‑canjen za su haifar da rage cutar zuciya a ainihi ba.
Raguwar lipids na iya zama sakamakon rage kiba ne kawai, ba tare da tasirin magani na musamman ba. Wannan binciken ba zai iya ware waɗannan abubuwan ba.
Abubuwan Da Za A Iya Amfani Da Su
Dose da tsawon lokaci. Babu wani shawarwarin dose da za a bi. Retatrutide har yanzu magani ne da ke cikin bincike. A cikin waɗannan gwaje‑gwajen an ba da kowane mako bisa ga tsarin binciken: 0.5–12 mg a Bincike 1 da 1–12 mg a Bincike 2, na tsawon makonni 36 ko 48. Waɗannan su ne hanyoyin gwaji, ba shawarwari ba.
Waɗanda suka shiga gwajin. Mutanen da aka nazarta su ne manyan mutane masu kiba ko overweight, ko da ba su da T2D. Matsakaicin BMI nasu ya kasance a tsakiyar 30‑s zuwa sama, kuma an bi su a asibiti.
Waɗanda ya kamata su guje shi. Kowane mutum da ke son samun retatrutide ba tare da shiga gwaji na doka ba ya kamata ya guje shi. Wannan ya haɗa da sayen maganin daga kasuwa marar tabbas ko “research chemical” a intanet. Samfurin ba a amince da shi ba, kuma ba za a iya tantance inganci, dose ko tsabtar sa ba. Ba shi ne kari ba, kuma ba za a iya amfani da shi a matsayin kari ba. Mutanen da ke da haɗarin cutar zuciya su tattauna hanyoyin da aka amince da su na kula da lipids tare da likita.
Abin da za a ci gaba da duba. Gwaje‑gwajen mataki na uku da manya‑manya, tare da bayanan sakamakon cutar zuciya, za su tantance ko waɗannan canje‑canjen alamomi za su tsaya da ƙima a ainihin rayuwa.
Ƙarshe
A cikin gwaje‑gwajen mataki na biyu guda biyu, retatrutide ya nuna manyan raguwar da aka daidaita da placebo a ApoB, cholesterol na non‑HDL, kwayoyin LDL da triglyceride‑rich lipoproteins. Haka kuma ya rage hsCRP da IL‑6 a gwajin da ba su da cutar sukari. Ƙididdigar suna da ban sha'awa, amma suna fitowa ne daga binciken bayan‑bayan na maganin da ba a amince da shi ba, kuma su ne canje‑canjen alamomi kawai, ba hujja ta tabbataccen amfanin lafiyar zuciya ba.
Source: Ruotolo et al., "Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes," Diabetes, Obesity & Metabolism. PubMed: 42608321. DOI: 10.1111/dom.71200.
